Core Viewpoint - The article highlights the innovative approach of Zhejiang Provincial People's Hospital's hepatobiliary and pancreatic surgery team in transforming late-stage cancer treatment through multidisciplinary collaboration and minimally invasive techniques, leading to significant improvements in patient outcomes [2][5]. Group 1: Patient Case Studies - A 56-year-old patient with late-stage pancreatic cancer, initially given a prognosis of 3-6 months, underwent a conversion chemotherapy regimen that allowed for successful surgical intervention, resulting in five years of disease-free survival [3][4]. - A 67-year-old patient with metastatic gallbladder cancer, previously deemed inoperable, received a combination of chemotherapy and PD-1 inhibitors, leading to significant tumor reduction and enabling robotic-assisted surgery, with no recurrence observed after two years [5][6]. Group 2: Treatment Innovations - Conversion chemotherapy has been shown to provide surgical opportunities for some late-stage pancreatic cancer patients, significantly increasing the five-year survival rate compared to traditional treatments [4]. - The surgical team conducts weekly multidisciplinary consultations to create personalized treatment plans, emphasizing the importance of reducing trauma and enhancing efficacy through technological innovations in minimally invasive surgery [6]. Group 3: Future Directions - The shift from a one-size-fits-all approach to individualized management in late-stage cancer treatment is evident, with a focus on combining conversion therapy, minimally invasive surgery, and supportive treatments to improve both survival rates and quality of life for patients [6].